PT  - JOURNAL ARTICLE
AU  - Peña-Hernández, Mario A.
AU  - Klein, Jon
AU  - Malik, Amyn A.
AU  - Coppi, Andreas
AU  - Kalinich, Chaney
AU  - Vogels, Chantal B. F.
AU  - Silva, Julio
AU - Yale SARS-CoV-2 Genomic Surveillance Initiative
AU  - Peaper, David R.
AU  - Landry, Marie-Louise
AU  - Wilen, Craig
AU  - Grubaugh, Nathan D.
AU  - Schulz, Wade
AU  - Omer, Saad B.
AU  - Iwasaki, Akiko
TI  - Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals
AID  - 10.1101/2021.12.28.21268460
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.12.28.21268460
4099  - http://medrxiv.org/content/early/2022/01/04/2021.12.28.21268460.short
4100  - http://medrxiv.org/content/early/2022/01/04/2021.12.28.21268460.full
AB  - The frequency of SARS-CoV-2 breakthrough infections in fully vaccinated individuals increased with the emergence of the Delta variant, particularly with longer time from vaccine completion. However, whether breakthrough infections lead to onward transmission remains unclear. Here, we conducted a study involving 125 patients comprised of 72 vaccinated and 53 unvaccinated individuals, to assess the levels of infectious virus in in vaccinated and unvaccinated individuals. Quantitative plaque assays showed no significant differences in the titers of virus between these cohorts. However, the proportion of nasopharyngeal samples with culturable virus was lower in the vaccinated patients relative to unvaccinated patients (21% vs. 40%). Finally, time-to-event analysis with Kaplan-Myer curves revealed that protection from culturable infectious virus waned significantly starting at 5 months after completing a 2-dose regimen of mRNA vaccines. These results have important implications in timing of booster dose to prevent onward transmission from breakthrough cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by research grants from Dr. Akiko Iwasaki.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Yale University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.